Healthcare Products Collaborative
FDA Continues Co-sponsorship of MedCon Conference with AFDO/RAPS Healthcare Products Collaborative.
View press release here: https://healthcareproducts.org/wp-content/uploads/2022/03/AFDO.RAPS-Collaborative-MedCon-FDA-Co-sponsor-Media-Release-.pdf
Regulatory Officials and Professionals Groups Form Partnership to Further Healthcare Products Industry Dialogue Including MedCon Conference.
View press release here: https://healthcareproducts.org/wp-content/uploads/2022/03/20220303_AFDO.RAPS-Collaborative-Media-Release.pdf
Considering Bias Without Bias
By Bill Whitford (DPS Group), Betsy Macht (Johnson & Johnson, retired), and Toni Manzano (Aizon) AI in Operations Bias in analysis or prediction is the disproportionate, improper weight or importance to an idea or thing. There are many sources of bias in analysis and modeling, and they can arise from the initial design of the … Read more
Data Governance: An AI in Pharma Requirement
By Toni Manzano (Aizon), Mario Stassen (Stassen Pharmaconsult BV), William Whitford (DPS Group) and AIO Team AI is a relatively mature field (officially born during the Dartmouth Conference in 1956) [1]. The current confluence of virtually unlimited data storage space and computational power has changed many aspects of algorithm design and implementation. For example, it … Read more
Modeling RNA Virus and Vaccine Structure
By William Whitford (DPS Group) Purpose: AI has applications throughout the value chain, and here we introduce an application in product development. AI in Modern Medicine Artificial Intelligence (AI) is one of the major techniques defining our modern era of medicine. The various machine learning algorithms employed in drug design include Supervised Learning, Unsupervised Learning, Semi-Supervised … Read more
In Their Own Words: Participants Review the AI Summit
By Mario Stassen (Stassen Pharmaconsult BV), William Whitford (DPS Group), and AIO Team Healthcare Products Collaborative (formerly Xavier Health) is committed to improving the progression of healthcare by supporting teams of representatives of academia, solution suppliers, and pharmaceutical product sponsors to discover and publish on the newest trends and technologies. In this blog entry by … Read more
AI in Pharma Adoption, Part 5: AI Value in Complex, Unstructured and Multiparametric Data
By Toni Manzano (Aizon), Mario Stassen (Stassen Pharmaconsult BV), William Whitford (DPS Group) and AIO Team AI is a combination of statistics, math, algorithms and software able to establish links between the complexity of reality and the emergence of specific behaviors created by the intricate relationships of the studied units. The human body is maybe … Read more
AI in Pharma Adoption, Part 4: Three Real Use Cases of AI Implementation in Pharma – NOT Science Fiction!
By Toni Manzano (Aizon), Mario Stassen (Stassen Pharmaconsult BV), William Whitford (DPS Group) and AIO Team In our last blog entry, we discussed the whats and whys around artificial intelligence (AI) transforming manufacturing. This entry sheds light upon some of the hows in anonymized accounts of real-life implementations. AI can present opportunities to improve production … Read more
AI in Pharma Adoption, Part 3: AI is Transforming Manufacturing—The Hows and Whys
By Toni Manzano (Aizon), Mario Stassen (Stassen Pharmaconsult BV), William Whitford (DPS Group) and AIO Team Artificial Intelligence (AI)-supported real-time monitoring and advanced data techniques provide many benefits in modern manufacturing operations. These include maintaining materials inventory, troubleshooting production bottlenecks, maintaining instruments in operating order, avoiding product quality excursions, understanding scrap rates, meeting promised delivery … Read more
